Can Cannabis Trigger Mental Illness? The Evidence Is Stronger Than Many People Think
Evidence review & editorial synthesis
Cannabis can produce relaxation, euphoria and altered perception. But in some people, the psychological effects appear to go much further.
A growing body of research links cannabis use with psychosis, bipolar disorder, depression, psychiatric relapse and poorer educational outcomes. The strongest evidence concerns psychosis, where risk rises with heavier use and several lines of evidence now point toward cannabis as a contributing cause rather than a harmless bystander.
A new study adds another warning for people who are already vulnerable: among young adults hospitalized with psychotic or bipolar disorders, cannabis users returned to psychiatric hospital substantially sooner.
Cannabis users returned to hospital sooner
The new study followed 200 adults aged 18 to 29 who had been hospitalized with psychotic or bipolar disorders.
Cannabis was common. Fifty-eight percent reported lifetime use and 43% were currently using it when admitted.
After discharge, cannabis use was associated with a markedly higher risk of early psychiatric readmission. During the first month, cannabis users had 2.8 times the hazard of rehospitalization. By three months, the hazard remained 1.9 times higher. By six months, the association was no longer statistically significant.
This does not prove cannabis caused the relapses. People who continue using cannabis may differ in illness severity, treatment adherence, social environment or other substance use.
But it fits a larger pattern: once psychotic or bipolar illness is established, cannabis use is repeatedly associated with a more difficult course.
The clearest risk is psychosis
The strongest evidence concerns schizophrenia and other psychotic disorders.
A meta-analysis involving 66,816 people found a clear dose-response relationship. The heaviest cannabis users had about 3.9 times the odds of schizophrenia or other psychotic outcomes compared with nonusers.
That pattern matters. If cannabis were merely something people with emerging psychosis happened to use, risk would not necessarily be expected to rise so consistently with exposure.
A massive 2026 study adds modern evidence. Researchers followed 463,396 adolescents who were routinely screened for cannabis use. Cannabis use during adolescence was associated with later psychotic disorders, bipolar disorder, depression and anxiety.
The association was strongest for psychosis and bipolar disorder. Cannabis users had an adjusted hazard ratio of 2.19 for psychotic disorders and 2.01 for bipolar disorder. Even after further accounting for prior psychiatric conditions, the associations remained elevated.
This still does not mean that everyone who uses cannabis faces a large absolute risk of schizophrenia. Most users do not develop psychosis. Vulnerability matters, and frequent use, younger age and high THC exposure appear particularly concerning.
The broader point is more important: cannabis is not psychologically neutral.
Depression and school outcomes show a wider pattern
The evidence becomes less certain outside psychosis, but it does not disappear.
A meta-analysis of 23,317 people who were followed from adolescence into adulthood found that adolescent cannabis use was associated with 37% higher odds of later depression and 50% higher odds of suicidal thoughts. The association with anxiety was not statistically significant in that analysis.
These are observational findings, so self-medication and shared risk factors remain plausible explanations for part of the association.
The effects may also extend beyond psychiatric diagnoses.
A 2024 meta-analysis combined 63 studies involving 438,329 adolescents and young adults. Cannabis use was associated with lower school grades, about twice the odds of dropping out and more than twice the odds of school absenteeism.
Users were also less likely to finish high school, enroll in university or earn a postsecondary degree. Earlier and more frequent use generally showed worse outcomes.
Interestingly, this does not appear to be explained by massive permanent cognitive impairment. A separate meta-analysis found only small average cognitive deficits in young frequent users, and those differences became very small and statistically nonsignificant in studies requiring more than 72 hours of abstinence.
That suggests a more complicated pathway involving intoxication, motivation, attendance, sleep, mental health, other substance use and disrupted routines rather than a simple story of permanent brain damage.
Risk depends heavily on who is using and how
Cannabis should not be treated as if every exposure has the same psychiatric meaning.
Someone using occasionally in adulthood is not in the same situation as a teenager using high-THC cannabis daily or a person recovering from a first psychotic episode.
The evidence points toward a risk gradient.
For psychosis, heavier exposure is consistently associated with greater risk. For adolescents, cannabis use is associated with a broader range of later psychiatric diagnoses. For people who already have psychotic or bipolar disorders, continued use may increase the chance of an unstable course and early readmission.
At the same time, observational research cannot perfectly separate cause from vulnerability. Some people use cannabis because they already feel anxious, depressed or emotionally unstable. Genetics and social factors can influence both drug use and mental illness.
That uncertainty matters, but it does not make the evidence meaningless.
The modern picture is no longer well summarized by saying cannabis is either harmless or universally dangerous. The risk appears concentrated in predictable groups: younger users, frequent users, people exposed to stronger THC and people with psychiatric vulnerability.
For those groups, the consequences can extend well beyond a temporary high.
Scientific References & Further Reading
- Anchor Study: “Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders.” (Perino J, Daveluy A, Truong-Bastos A, Miremont F, Fatseas M, Tournier M. J Clin Psychiatry. 2026;87(4):25m16257. doi:10.4088/jcp.25m16257.)
- Adolescent Psychiatric Disorders: “Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.” (Young-Wolff KC, Cortez CA, Alexeeff SE, et al. JAMA Health Forum. 2026;7(2):e256839. doi:10.1001/jamahealthforum.2025.6839.)
- Psychosis Dose Response: “Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.” (Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Schizophr Bull. 2016;42(5):1262-1269. doi:10.1093/schbul/sbw003.)
- Depression and Suicidality: “Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood.” (Gobbi G, Atkin T, Zytynski T, et al. JAMA Psychiatry. 2019;76(4):426-434. doi:10.1001/jamapsychiatry.2018.4500.)
- Academic Outcomes: “Cannabis Use During Adolescence and Young Adulthood and Academic Achievement.” (Chan O, Daudi A, Ji D, et al. JAMA Pediatr. 2024;178(12):1280-1289. doi:10.1001/jamapediatrics.2024.3674.)
- Cognitive Effects: “Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults.” (Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. JAMA Psychiatry. 2018;75(6):585-595. doi:10.1001/jamapsychiatry.2018.0335.)
Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.

